Asparagus Polysaccharide and Gum with Hepatic Artery Embolization Induces Tumor Growth and Inhibits Angiogenesis in an Orthotopic Hepatocellular Carcinoma Model

  • Weng, Ling-Ling ;
  • Xiang, Jian-Feng ;
  • Lin, Jin-Bo ;
  • Yi, Shang-Hui ;
  • Yang, Li-Tao ;
  • Li, Yi-Sheng ;
  • Zeng, Hao-Tao ;
  • Lin, Sheng-Ming ;
  • Xin, Dong-Wei ;
  • Zhao, Hai-Liang ;
  • Qiu, Shu-Qi ;
  • Chen, Tao ;
  • Zhang, Min-Guang
  • Published : 2015.01.22


Liver cancer is one of leading digestive malignancies with high morbidity and mortality. There is an urgent need for the development of novel therapies for this deadly disease. It has been proven that asparagus polysaccharide, one of the most active derivates from the traditional medicine asparagus, possesses notable antitumor properties. However, little is known about the efficacy of asparagus polysaccharide as an adjuvant for liver cancer chemotherapy. Herein, we reported that asparagus polysaccharide and its embolic agent form, asparagus gum, significantly inhibited liver tumor growth with transcatheter arterial chemoembolization (TACE) therapy in an orthotopic hepatocellular carcinoma (HCC) tumor model, while significantly inhibiting angiogenesis and promoting tumor cell apoptosis. Moreover, asparagine gelatinous possessed immunomodulatory functions and showed little toxicity to the host. These results highlight the chemotherapeutic potential of asparagus polysaccharide and warrant a future focus on development as novel chemotherapeutic agent for liver cancer TACE therapy.


Hepatocellular carcinoma (HCC);asparagus gum;asparagus polysaccharide;TACE therapy


  1. Boatright KM, Salvesen GS (2003). Mechanisms of caspase activation. Curr Opinion Cell Biol, 15, 725-31.
  2. Buijs M, Vossen JA, Frangakis C, et al (2008). Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. Radiology, 249, 346-54.
  3. Chen T, Xu Y, Guo H, et al (2011). Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One, 6, 20729.
  4. Chun J, Cheon M, Moon B, et al (2011). Anti-tumor activity of the ethyl acetate fraction from Asparagus cochinchinensis in HepG2-xenografted nude mice. J Kor SocAppl Biol Chem, 54, 538-43.
  5. Czabotar PE, Lessene G, Strasser A, et al (2013). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature Reviews Molecular Cell Biol, 15, 49-63.
  6. Deng G, Zhao DL, Li GC, et al (2011). Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. Cardiovasc Intervent Radiol, 34, 824-32.
  7. Graf D, Vallbohmer D, Knoefel WT, et al (2014). Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med, 25, 430-7.
  8. Horak ER, Leek R, Klenk N, et al (1992). Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet, 340, 1120-4.
  9. Idee JM, Guiu B (2013). Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol, 88, 530-49.
  10. Kuida K, Zheng TS, Na S, et al (1996). Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature, 384, 368-72.
  11. Kumar S (2007). Caspase function in programmed cell death. Cell Death Differ, 14, 32-43.
  12. Peng S, Yang QX, Zhang T, et al (2014). Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 5155-60.
  13. Poon RT, Lau C, Yu WC, et al (2004). High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep, 11, 1077-84.
  14. Ravaioli M, Ercolani G, Neri F, et al (2014). Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol, 20, 5345-52.
  15. Rou WS, Lee BS, Moon HS, et al (2014). Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol, 20, 6995-7004.
  16. Samad NB, Debnath T, Abul Hasnat M, et al (2014). Phenolic contents, antioxidant and anti-inflammatory activities of Asparagus cochinchinensis( Loureiro) Merrill. J Food Biochemistry, 38, 83-91.
  17. Sergio A, Cristofori C, Cardin R, et al (2008). Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol, 103, 914-21.
  18. Shim JH, Park JW, Kim JH, et al (2008). Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci, 99, 2037-44.
  19. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.
  20. Thakur M, Connellan P, Deseo MA, et al (2012). Characterization and in vitro immunomodulatory screening of fructo-oligosaccharides of Asparagus racemosus Willd. Int J Biol Macromol, 50, 77-81.
  21. Volkmann N, Marassi FM, Newmeyer DD, et al (2014). The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ, 21, 206-15.
  22. Wang B, Xu H, Gao ZQ, et al (2008). Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol, 49, 523-9.
  23. Weidner N, Semple JP, Welch WR, et al (1991). Tumor angiogenesis and metastasis . correlation in invasive breast carcinoma. New Engl J Med, 324, 1-8.
  24. Xiang J, Xiang Y, Lin S, et al (2014). Anticancer effects of deproteinized asparagus polysaccharide on hepatocellular carcinoma in vitro and in vivo. Tumour Biol, 35, 3517-24.
  25. xing D-w (2005). The haemolytic experiment of Aspartame colloid Lishizhen Medicine and Materia medica research, 16, 1067-8.
  26. Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6.
  27. Yu Bin J, Chen Feng J, Yong Cui M (2010). Notice of Retraction
    Effect of Asparagus polysaccharide on the number and activity of erythrocyte complement receptor 1(CD35) of S180 mice. Environmental Science and Information Application Technology (ESIAT), 2010 International Conference on, 2010. 716-9.
  28. Zhang MG (2003). Study on of toxicity of Aspartame colloid as vascular embolization agent -preliminary experimence. Chin Imag J Integr Trad Western Med, 1, 21-2.
  29. Zhao Q, Xie B, Yan J, et al (2012). In vitro antioxidant and antitumor activities of polysaccharides extracted from Asparagus officinalis. Carbohydrate Polymers, 87, 392-6.

Cited by

  1. Dietary Natural Products for Prevention and Treatment of Liver Cancer vol.8, pp.3, 2016,
  2. An Asparagus polysaccharide fraction inhibits MDSCs by inducing apoptosis through toll-like receptor 4 vol.32, pp.7, 2018,


Supported by : National Natural Science Foundation of China